In which patients with ulcerative colitis would filgotinib be effective? [0.03%]
filgotinib治疗溃疡性结肠炎的有效人群是哪些？
Jihye Park
Jihye Park
Burden of inflammatory bowel disease in India: analysis of the Global Burden of Disease study from 1990 to 2019 [0.03%]
1990年至2019年印度炎症性肠病疾病负担：全球疾病负担研究分析结果
Suprabhat Giri,Anuraag Jena,Praveen Kumar-M et al.
Suprabhat Giri et al.
Background/aims: Inflammatory bowel disease (IBD) is increasing across the globe, more so in populous countries like India. We aimed to study the disease burden and epidemiological trends of IBD in India and look closer i...
Propensity score-matched real-world comparative treatment outcomes of Janus kinase inhibitors for ulcerative colitis in patients with and without prior exposure to anti-tumor necrosis factor α antibody [0.03%]
Janus激酶抑制剂治疗抗肿瘤坏死因子α抗体既往暴露患者和未暴露患者的溃疡性结肠炎的真实世界对比结局：倾向得分匹配分析
Maiko Ikenouchi,Hirokazu Fukui,Soichi Yagi et al.
Maiko Ikenouchi et al.
Background/aims: Tofacitinib (TFB), filgotinib (FIL), and upadacitinib (UPA) are Janus kinase (JAK) inhibitors approved for moderate-to-severe ulcerative colitis (UC). The appropriate positioning of each JAK inhibitor in ...
Short-term and long-term outcomes of acute severe ulcerative colitis in Taiwan: a multicenter study with pre- and post-biologics comparison [0.03%]
台湾急性重症溃疡性结肠炎的短期和长期结局：生物制剂使用前与使用后的多中心研究比较分析
Wei-Chen Lin,Chun-Chi Lin,Wen-Hung Hsu et al.
Wei-Chen Lin et al.
Background/aims: Data from Asia regarding the short-term and long-term outcomes for acute severe ulcerative colitis (ASUC) are limited. We assessed the outcomes of ASUC, identified the risk factors for colectomy, and comp...
Real-world use of biologics during the first year of treatment for newly diagnosed Crohn's disease in Japan: a claims analysis from 2010 to 2021 [0.03%]
日本2010年至2021年新诊断克罗恩病患者生物制剂初始治疗一年内的真实世界应用：基于理赔数据分析
Jun Miyoshi,Annabelle Yoon,Minoru Matsuura et al.
Jun Miyoshi et al.
Background/aims: Crohn's disease (CD) leads to bowel damage and disability if suboptimally treated. We investigated firstyear treatment decisions and real-world use of biologics in patients with CD in Japan. ...
Prevalence and outcome of sarcopenia in patients with inflammatory bowel disease: a follow-up study [0.03%]
炎症性肠病患者 sarcopenia 的患病率和结局：一项随访研究
Vikram Dharap,Devendra Desai,Philip Abraham et al.
Vikram Dharap et al.
Background/aims: Sarcopenia is implicated in inflammatory bowel disease (IBD) complications and surgical outcomes. This study aimed to investigate the prevalence and follow-up of sarcopenia in patients with IBD. ...
Understanding fatigue among Japanese patients with inflammatory bowel disease: insights from international comparisons and meta-analysis [0.03%]
日本炎症性肠病患者的疲劳状况：国际比较和meta分析的启示
Makoto Tanaka,Momoko Takai,Sayaka Wakai et al.
Makoto Tanaka et al.
Background/aims: Fatigue is a common symptom in patients with inflammatory bowel disease (IBD). The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale has demonstrated reliability and validity in ass...
Endoscopic radial incision and cutting using balloonassisted enteroscopy for small intestinal stenosis related to Crohn's disease: a pilot study [0.03%]
经内镜肠道 balloon 助行下小肠狭窄切开及切除术治疗克罗恩病相关性狭窄：一项前瞻性研究
Rintaro Moroi,Kotaro Nochioka,Satoshi Miyata et al.
Rintaro Moroi et al.
Background/aims: Radial incision and cutting (RIC) is an alternative dilation method for stenosis of the lower gastrointestinal tract. However, its safety and efficacy for the small intestine requiring balloon-assisted en...
Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study [0.03%]
影响溃疡性结肠炎患者坚持使用维多珠单抗治疗的一年因素：一项基于真实世界的多中心回顾性研究
Taku Kobayashi,Tadakazu Hisamatsu,Satoshi Motoya et al.
Taku Kobayashi et al.
Background/aims: The objectives of this real-world study were to determine 1-year persistence with vedolizumab in patients with ulcerative colitis and to evaluate factors contributing to loss of response. ...